Skip to content

Study · Randomized controlled trial · n = 255 · 2022

4 results

RF32 | PSUN59 Glucagon-Like Peptide-1 Analogues: A New Way to Quit Smoking? SKIP – a Randomised Controlled Study

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9625035 (opens in a new tab)PepBankPUB-95692125
Read at sourceSource pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In smokers, dulaglutide did not improve abstinence versus placebo: 63% versus 65%.

    In plain wordsIn smokers, dulaglutide did not improve quitting rates compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSmoking abstinence
    Study

    n = 255

    Comparator
    Placebo with standard care
    Analysis
    Primary
    Outcome group
    Addiction, withdrawal and alcohol intake · Respiratory
    Studied dose
    1.5 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Abstinence
    63%
    dulaglutide
    Abstinence
    65%
    placebo
    Difference in proportions
    −1.9%
    versus placebo

    Source sentences

    Summary
    The point-prevalence abstinence rate after 12 weeks of treatment was 80/127 (63%) in the dulaglutide group and 82/128 (65%) in the placebo group (difference in proportions [95% CI] -1.9% [-10.7, 14.4], p=0.859).
    2 context sentences
    Summary · context
    This was a placebo-controlled, double-blind, parallel group, superiority, single-center randomized study including 255 patients.
    Summary · context
    The intervention consisted of a 12-week treatment phase with dulaglutide 1.5 mg or placebo injected subcutaneously at a weekly study visit, in addition to standard of care (behavioral counselling and pharmacotherapy with varenicline).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In smokers, dulaglutide reduced weight versus placebo, with an adjusted difference of -2.5 kg.

    In plain wordsIn smokers, dulaglutide reduced weight compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight change
    Study

    n = 255

    Comparator
    Placebo with standard care
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Weight change
    −0.7 kg
    dulaglutide
    Weight change
    1.8 kg
    placebo
    Adjusted weight difference
    −2.5 kg
    versus placebo

    Source sentences

    Summary
    We observed an increase in weight in the placebo (+1.8kg [SD 2.4]) and a decrease in the dulaglutide group (-0.7kg [SD 3.3]) between baseline and week 12; baseline-adjusted difference in weight change [95% CI] -2.5kg [-3.3, -1.7], p<0.001.
    2 context sentences
    Summary · context
    This was a placebo-controlled, double-blind, parallel group, superiority, single-center randomized study including 255 patients.
    Summary · context
    The intervention consisted of a 12-week treatment phase with dulaglutide 1.5 mg or placebo injected subcutaneously at a weekly study visit, in addition to standard of care (behavioral counselling and pharmacotherapy with varenicline).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In smokers, cue-induced craving decreased from baseline to week 12 overall, with no difference between dulaglutide and placebo.

    In plain wordsIn smokers, craving fell from baseline overall, with no difference between dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSmoking cue craving
    Study

    n = 71

    Comparator
    Placebo with standard care
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    1.5 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Craving change from baseline to week 12
    −3 VAS units
    overall
    Between-group difference in craving
    0.4 VAS units
    dulaglutide versus placebo

    Source sentences

    Summary
    Craving in response to smoking cue videos decreased from baseline to week 12 (estimated mean difference [95% CI] -3.0 [-3.7, -2.3], p<0.001), with no difference between dulaglutide and placebo (estimated mean difference [95% CI] 0.4 [-1.2, 2.0], p=0.6).
    3 context sentences
    Summary · context
    In a substudy (n=71), we compared behavioral (i.e., nicotine craving measured by a Visual Analogue Scale from 1-7) and brain activity changes in response to smoking cue videos using functional magnetic resonance imaging (fMRI) at baseline and week 12.
    Summary · context
    This was a placebo-controlled, double-blind, parallel group, superiority, single-center randomized study including 255 patients.
    Summary · context
    The intervention consisted of a 12-week treatment phase with dulaglutide 1.5 mg or placebo injected subcutaneously at a weekly study visit, in addition to standard of care (behavioral counselling and pharmacotherapy with varenicline).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In smokers, brain functional activity did not differ between dulaglutide and placebo at either assessment or in change over time.

    In plain wordsIn smokers, brain activity did not differ between dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeWhole brain functional activity
    Study

    n = 71

    Comparator
    Placebo with standard care
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.5 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Similarly, no difference in whole brain functional activity was seen between the two treatments, at both time points and between baseline and follow up.
    3 context sentences
    Summary · context
    In a substudy (n=71), we compared behavioral (i.e., nicotine craving measured by a Visual Analogue Scale from 1-7) and brain activity changes in response to smoking cue videos using functional magnetic resonance imaging (fMRI) at baseline and week 12.
    Summary · context
    This was a placebo-controlled, double-blind, parallel group, superiority, single-center randomized study including 255 patients.
    Summary · context
    The intervention consisted of a 12-week treatment phase with dulaglutide 1.5 mg or placebo injected subcutaneously at a weekly study visit, in addition to standard of care (behavioral counselling and pharmacotherapy with varenicline).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.